OPTIC is revolutionizing the pharmaceutical sector with its AI-powered drug discovery platform, enabling rapid molecule screening and testing from target identification to lab validation. The company, founded in 2021, is leveraging cutting-edge AI to automate biotech R&D processes.
Originally conceived as an AI research team focused on developing high-performance similarity search algorithms, OPTIC has successfully expanded its proprietary technology's applicability across various industries such as blockchain and biotech. Headquartered in the United States, OPTIC operates under the umbrellas of AI, Information Technology, SaaS, and Web3.
The company attracted attention with a significant $11.00M Seed Round investment on July 20, 2022, backed by renowned investors like Pantera Capital, Kleiner Perkins, Flamingo DAO, Circle, Lattice Capital, Neon DAO, Polygon, OpenSea, Greylock, and CoinDCX Ventures. These strategic partnerships underscore OPTIC's potential in transforming AI-driven solutions for drug discovery.